Hyloris Pharmaceuticals SA (HYL.BR)
EUR 5.8
(-1.36%)
EUR 5.8
(-1.36%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.55 EUR | -37.5% |
| 2022 | -0.40 EUR | 11.11% |
| 2021 | -0.45 EUR | -60.71% |
| 2020 | -0.28 EUR | 75.65% |
| 2019 | -1.15 EUR | -360.0% |
| 2018 | -0.25 EUR | -56.25% |
| 2017 | -0.16 EUR | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 Q2 | -0.12 EUR | 0.0% |
| 2023 Q3 | -0.16 EUR | -33.33% |
| 2023 Q1 | - EUR | 100.0% |
| 2023 FY | - EUR | -37.5% |
| 2023 Q4 | -0.16 EUR | 0.0% |
| 2022 Q2 | -0.19 EUR | -100.0% |
| 2022 FY | - EUR | 11.11% |
| 2022 Q4 | -0.12 EUR | 0.0% |
| 2022 Q3 | -0.12 EUR | 36.84% |
| 2022 Q1 | -0.10 EUR | 26.92% |
| 2021 FY | - EUR | -60.71% |
| 2021 Q4 | -0.13 EUR | -100.0% |
| 2021 Q3 | -0.06 EUR | 79.69% |
| 2021 Q2 | -0.32 EUR | -100.0% |
| 2021 Q1 | -0.16 EUR | -139.16% |
| 2020 Q2 | -0.10 EUR | -49.03% |
| 2020 FY | - EUR | 75.65% |
| 2020 Q4 | -0.07 EUR | 0.0% |
| 2020 Q1 | -0.07 EUR | 66.45% |
| 2020 Q3 | -0.07 EUR | 33.1% |
| 2019 Q2 | -0.02 EUR | 16.04% |
| 2019 Q3 | -0.20 EUR | -713.01% |
| 2019 Q1 | -0.03 EUR | 0.0% |
| 2019 FY | - EUR | -360.0% |
| 2019 Q4 | -0.20 EUR | 0.0% |
| 2018 FY | - EUR | -56.25% |
| 2017 FY | - EUR | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| ABIONYX Pharma SA | -0.12 EUR | -358.333% |
| ABIVAX Société Anonyme | -3.43 EUR | 83.965% |
| Adocia SA | -1.91 EUR | 71.204% |
| Aelis Farma SA | -0.39 EUR | -41.026% |
| Biophytis S.A. | -12.55 EUR | 95.618% |
| Advicenne S.A. | -0.67 EUR | 17.91% |
| genOway Société anonyme | 0.17 EUR | 423.529% |
| IntegraGen SA | -0.03 EUR | -2023.552% |
| Medesis Pharma S.A. | -0.80 EUR | 31.25% |
| Neovacs S.A. | -0.00 EUR | -21900.0% |
| NFL Biosciences SA | -0.46 EUR | -19.565% |
| Plant Advanced Technologies SA | 0.07 EUR | 885.714% |
| Quantum Genomics Société Anonyme | -0.09 EUR | -504.396% |
| Sensorion SA | -0.17 EUR | -223.529% |
| Theranexus Société Anonyme | -0.88 EUR | 37.5% |
| TME Pharma N.V. | -1.34 EUR | 58.955% |
| Valbiotis SA | -0.59 EUR | 6.78% |
| TheraVet SA | -0.49 EUR | -12.245% |
| Valerio Therapeutics Société anonyme | -0.15 EUR | -266.667% |
| argenx SE | -4.67 EUR | 88.223% |
| BioSenic S.A. | -0.21 EUR | -161.905% |
| Celyad Oncology SA | -0.33 EUR | -66.667% |
| DBV Technologies S.A. | -0.71 EUR | 22.535% |
| Galapagos NV | 3.21 EUR | 117.134% |
| Genfit S.A. | -0.58 EUR | 5.172% |
| GeNeuro SA | -0.59 EUR | 6.78% |
| Innate Pharma S.A. | -0.09 EUR | -484.485% |
| Inventiva S.A. | -2.43 EUR | 77.366% |
| MaaT Pharma SA | -1.73 EUR | 68.208% |
| MedinCell S.A. | -0.88 EUR | 37.5% |
| Nanobiotix S.A. | -1.08 EUR | 49.074% |
| Onward Medical N.V. | -1.20 EUR | 54.167% |
| Oryzon Genomics S.A. | -0.06 EUR | -898.185% |
| OSE Immunotherapeutics SA | -1.18 EUR | 53.39% |
| Oxurion NV | -0.01 EUR | -4682.609% |
| Pharming Group N.V. | -0.01 EUR | -3693.103% |
| Poxel S.A. | -0.91 EUR | 39.56% |
| GenSight Biologics S.A. | -0.54 EUR | -1.852% |
| Transgene SA | -0.22 EUR | -150.0% |
| Financière de Tubize SA | 1.98 EUR | 127.778% |
| UCB SA | 1.81 EUR | 130.387% |
| Valneva SE | -0.73 EUR | 24.658% |
| Vivoryon Therapeutics N.V. | -1.12 EUR | 50.893% |